It allows continued monitoring of the benefit/risk balance of the medicinal product. Olmesartan medoxomil and hydrochlorothiazide is not indicated for the initial therapy of hypertension Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on olmesartan medoxomil and hydrochlorothiazide 70756-814-30, Use of olmesartan medoxomil is not recommended in patients with severe renal impairment (creatinine clearance < 20 ml/min) (see sections 4.2 and 5.2). Buy Olmesartan Online. If up-titration to the maximum dose of 40 mg daily is required, blood pressure should be closely monitored.The maximum dose in patients with mild to moderate renal impairment (creatinine clearance of 20 – 60 ml/min) is 20 mg olmesartan medoxomil once daily, owing to limited experience of higher dosages in this patient group. No dose adjustment is required in patients with mild (CrCl 60-90 mL/min) or moderate (CrCl 30-60) renal impairment.No lethality was observed in acute toxicity studies in mice and rats given single oral doses up to 2000 mg/kg olmesartan medoxomil. This may be at least in part related to a mean decrease in renal function in this group of patients.In renally impaired patients, the AUC at steady state increased by 62%, 82% and 179% in patients with mild, moderate and severe renal impairment, respectively, compared to healthy controls (see sections 4.2 and 4.4).After single oral administration, olmesartan AUC values were 6% and 65% higher in mildly and moderately hepatically impaired patients, respectively, than in their corresponding matched healthy controls. If diarrhoea does not improve during the week after the discontinuation, further specialist (e.g. The onset of the antihypertensive effect occurred within 1 week and was largely manifest after … How to use Olmesartan MEDOXOMIL. Such conditions should be corrected before the administration of olmesartan medoxomil.In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. Olmesartan (Benicar) is an oral medication used to treat high blood pressure. Coadministration of warfarin and digoxin had no effect on the pharmacokinetics of olmesartan.Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists. The risk of the concomitant use of NSAIDs and angiotensin II receptor antagonists is the occurrence of acute renal failure. If a patient develops these symptoms during treatment with olmesartan, exclude other etiologies. Take this medication by mouth as directed by your doctor, usually once daily with or without food. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Once-daily dosing with 20 mg olmesartan medoxomil and 12.5 mg hydrochlorothiazide, 40 mg olmesartan medoxomil and 12.5 mg hydrochlorothiazide or 40 mg olmesartan medoxomil and 25 mg hydrochlorothiazide produced mean placebo-adjusted blood pressure reductions at trough (24 hours post-dosing) ranging from 17/8 to 24/14 mm Hg. Monitor renal function periodically in patients receiving olmesartan medoxomil and NSAID therapy.The antihypertensive effect of angiotensin II receptor antagonists, including olmesartan medoxomil may be attenuated by NSAIDs including selective COX-2 inhibitors.In some patients the administration of a NSAID can reduce the diuretic, natriuretic, and antihypertensive effects of thiazide diuretics.